Columbia Laboratories Inc (CBRX)

6.19
1.76 22.14
NASDAQ : Health Care
Prev Close 7.95
Open 8.05
Day Low/High 6.17 / 8.10
52 Wk Low/High 5.09 / 15.44
Volume 155.03K
Avg Volume 58.70K
Exchange NASDAQ
Shares Outstanding 10.78M
Market Cap 79.30M
EPS 0.31
P/E Ratio 27.26
Div & Yield N.A. (N.A)

Latest News

Amended Class Action Lawsuit Against Columbia Laboratories Dismissed Without Prejudice

Amended Class Action Lawsuit Against Columbia Laboratories Dismissed Without Prejudice

Columbia Laboratories, Inc. (Nasdaq:CBRX) announced today that the previously disclosed Consolidated Second Amended Class Action Complaint to the putative class action lawsuit filed against the Company, Actavis, Inc.

Molecular Profiles Selected To Develop Topical & Oral Psoriasis Products For Telormedix

Molecular Profiles Selected To Develop Topical & Oral Psoriasis Products For Telormedix

Pharmaceutical formulation development and manufacturing services provider Molecular Profiles Ltd.

Columbia Laboratories Expands Board Of Directors

Columbia Laboratories Expands Board Of Directors

Columbia Laboratories, Inc. (Nasdaq:CBRX) today announced that its Board of Directors has appointed three experienced healthcare executives with over 65 years collective industry experience to its Board of Directors, ...

Columbia Laboratories Acquires Molecular Profiles Ltd., A U.K.-Based Provider Of Pharmaceutical Formulation Development And Manufacturing Services

Columbia Laboratories Acquires Molecular Profiles Ltd., A U.K.-Based Provider Of Pharmaceutical Formulation Development And Manufacturing Services

Columbia Laboratories Inc. (NasdaqCM:CBRX) [“Columbia”, the “Company”] has acquired Molecular Profiles Ltd.

Columbia Laboratories Regains Compliance With Nasdaq Listing Standards

Columbia Laboratories Regains Compliance With Nasdaq Listing Standards

Columbia Laboratories, Inc. (NasdaqCM:CBRX) received notice on August 23, 2012, from the Nasdaq Stock Market that the Company has regained compliance with the Nasdaq Stock Market minimum bid price requirement as set...

Columbia Laboratories Announces One-for-Eight Reverse Stock Split

Columbia Laboratories Announces One-for-Eight Reverse Stock Split

Columbia Laboratories, Inc. (“Columbia” or the “Company”) (NasdaqCM: CBRX) announced a 1-for-8 reverse split of its Common Stock, par value $0.

Columbia Laboratories Reports Second Quarter 2013 Financial Results

Columbia Laboratories Reports Second Quarter 2013 Financial Results

Columbia Laboratories, Inc. (NasdaqCM: CBRX) today reported financial results for the three and six-month periods ended June 30, 2013.

Columbia Laboratories’ Board Approves 1-for-8 Reverse Stock Split

Columbia Laboratories’ Board Approves 1-for-8 Reverse Stock Split

Columbia Laboratories, Inc. (“Columbia” or the “Company”) (NasdaqCM: CBRX) announced today that its Board of Directors (the “Board”) has set a ratio of 1-for-8 for its previously approved...

Columbia Laboratories To Discuss Second Quarter 2013 Financial Results On August 7 Conference Call

Columbia Laboratories To Discuss Second Quarter 2013 Financial Results On August 7 Conference Call

Columbia Laboratories, Inc. (NasdaqCM: CBRX) will hold a conference call on August 7, 2013, to discuss financial results of the second quarter ended June 30, 2013.

Plaintiffs Amend Previously Dismissed Class Action Lawsuit Against Columbia Laboratories

Plaintiffs Amend Previously Dismissed Class Action Lawsuit Against Columbia Laboratories

Columbia Laboratories, Inc. (NasdaqCM: CBRX) announced today that plaintiffs in the putative class action lawsuit filed against the Company, Actavis, Inc.

Columbia Laboratories Announces Completion Of Corporate Relocation

Columbia Laboratories Announces Completion Of Corporate Relocation

Columbia Laboratories, Inc. (NasdaqCM: CBRX) announced today that the Company has completed the relocation of its corporate headquarters from Livingston, New Jersey, to Boston, Massachusetts.

Healthcare Sector: High Quality Stocks At A Great Value

Healthcare Sector: High Quality Stocks At A Great Value

Nick Sousa, Kapitall:  Analysts are favoring the healthcare sector in 2013 due to strong projected growth supported by an aging [...]

Columbia Laboratories Reports Fourth Quarter And Year-End 2012 Financial Results

Columbia Laboratories Reports Fourth Quarter And Year-End 2012 Financial Results

Columbia Laboratories, Inc. (Nasdaq: CBRX) today reported financial results for the three- and twelve-month periods ended December 31, 2012.

Columbia Laboratories Extends Stockholder Rights Plan To Preserve Use Of Net Operating Losses Under Section 382

Columbia Laboratories Extends Stockholder Rights Plan To Preserve Use Of Net Operating Losses Under Section 382

Columbia Laboratories, Inc. (Nasdaq: CBRX) (the “Company”) today announced that its Board of Directors on March 1, 2013 adopted an amendment to its Stockholder Rights Plan (the "Rights Plan"), originally ...

Columbia Laboratories To Discuss Fourth Quarter And Year-End 2012 Financial Results On March 14 Conference Call

Columbia Laboratories To Discuss Fourth Quarter And Year-End 2012 Financial Results On March 14 Conference Call

Columbia Laboratories Inc. (Nasdaq: CBRX) will hold a conference call on March 14, 2013, to discuss financial results of the fourth quarter and year ended December 31, 2012.

Columbia Laboratories To Present March 6th At Cowen And Company Health Care Conference

Columbia Laboratories To Present March 6th At Cowen And Company Health Care Conference

Columbia Laboratories Inc. (Nasdaq: CBRX) announced today that Frank Condella, President and Chief Executive Officer will present at the Cowen and Company 33 rd Annual Health Care conference.

Jonathan B. Lloyd Jones Appointed CFO Of Columbia Laboratories

Jonathan B. Lloyd Jones Appointed CFO Of Columbia Laboratories

Columbia Laboratories Inc. (Nasdaq: CBRX) today announced the appointment of Jonathan B.

Columbia Laboratories Reports Third Quarter 2012 Financial Results

Columbia Laboratories Reports Third Quarter 2012 Financial Results

Columbia Laboratories, Inc. (Nasdaq: CBRX) today reported financial results for the three- and nine-month periods ended September 30, 2012.

Columbia Laboratories Expects Ongoing Email And Phone Outages Into Next Week

Columbia Laboratories Expects Ongoing Email And Phone Outages Into Next Week

Due to severe weather related to Hurricane Sandy, Columbia Laboratories Inc.

Columbia Laboratories Confirms FDA Denies Watson’s Appeal Related To Prochieve NDA For The Prevention Of Preterm Birth

Columbia Laboratories Confirms FDA Denies Watson’s Appeal Related To Prochieve NDA For The Prevention Of Preterm Birth

Columbia Laboratories Inc. (Nasdaq: CBRX) today confirmed that the U.

Columbia Laboratories To Discuss Third Quarter 2012 Financial Results On November 8 Conference Call

Columbia Laboratories To Discuss Third Quarter 2012 Financial Results On November 8 Conference Call

Columbia Laboratories Inc. (Nasdaq: CBRX) will hold a conference call on November 8, 2012, to discuss financial results of the three-month period ended September 30, 2012.

Columbia Laboratories Receives Nasdaq Minimum Bid Price Non-compliance Letter

Columbia Laboratories Receives Nasdaq Minimum Bid Price Non-compliance Letter

Columbia Laboratories Inc. (Nasdaq: CBRX) (the “Company”) received a letter on October 24, 2012, from the Nasdaq Stock Market indicating that the Company no longer meets the minimum bid price requirement for ...

Columbia Laboratories Regains Compliance With Nasdaq Listing Standards

Columbia Laboratories Regains Compliance With Nasdaq Listing Standards

Columbia Laboratories Inc. (Nasdaq: CBRX) received a notice on September 6, 2012, from the Nasdaq Stock Market indicating that the Company has regained compliance with the minimum bid price requirement for continued ...

Columbia Laboratories Will Present On September 6 At Stifel Nicolaus Healthcare Conference

Columbia Laboratories Will Present On September 6 At Stifel Nicolaus Healthcare Conference

Columbia Laboratories Inc. (Nasdaq: CBRX) announced today that Frank Condella, president and chief executive officer, will present at the Stifel Nicolaus 2012 Healthcare Conference.

Columbia Laboratories's CEO Discusses Q2 2012 Results - Earnings Call Transcript

Columbia Laboratories's CEO Discusses Q2 2012 Results - Earnings Call Transcript

Columbia Laboratories's CEO Discusses Q2 2012 Results - Earnings Call Transcript

Columbia Laboratories Reports Second Quarter 2012 Financial Results

Columbia Laboratories Reports Second Quarter 2012 Financial Results

Columbia Laboratories, Inc. (Nasdaq: CBRX) today reported financial results for the three- and six- month periods ended June 30, 2012.

Columbia Laboratories To Discuss Second Quarter 2012 Financial Results On August 8, 2012, Conference Call

Columbia Laboratories To Discuss Second Quarter 2012 Financial Results On August 8, 2012, Conference Call

Columbia Laboratories Inc. (Nasdaq: CBRX) will hold a conference call on August 8, 2012, to discuss financial results of the three- and six-month periods ended June 30, 2012.